

C - Reactive Protein and Coronary Calcium Score Association in Coronary Artery Disease

Ali Hosseinsabet, Bahram Mohebbi, Ahmad Mohebbi
and Alireza Almasi

Abstract

Objectives- Both high-sensitivity C-reactive protein (hs-CRP) and spiral computed tomography coronary artery calcium score are valid markers of cardiovascular risk. It is unknown whether hs-CRP is a marker of atherosclerotic burden or whether it reflects a process leading to acute coronary events.

Methods- We studied the association of high-sensitivity C-reactive protein and coronary calcium score in 143 patients that were candidates for coronary artery bypass graft surgery.

Results- In our cross sectional study we found no significant association between high-sensitivity C-reactive protein and coronary calcium score in bivariable ($p=0.162$) and multivariable ($p=0.062$) analysis, but in patients who did not use statins, this association was significant and positive in bivariable ($p=0.001$) and in multivariable analysis this association was negative and significant ($p=0.008$).

Conclusion- High-sensitivity C-reactive protein was not associated with coronary calcium score. The relation between C-reactive protein and clinical events might not be related to atherosclerotic burden. Measures of inflammation, such as C-reactive protein, and indices of atherosclerosis, such as coronary calcium score, are likely to provide distinct information regarding cardiovascular risk (*Iranian Heart Journal 2009; 10 (1):40-47*).

Key words: coronary calcification ■ C-reactive protein ■ inflammation ■ atherosclerosis ■ risk factors

Much evidence exists to suggest that inflammation plays a major role in the development of atherosclerosis and its clinical manifestations.^{1,2} In some studies, plasma levels of inflammatory markers, particularly C-reactive protein (CRP), predict myocardial infarction and cardiovascular death.³⁻⁸ However, CRP is associated with many established risk factors, including dyslipidemia, cigarette smoking, hypertension, diabetes and obesity⁹⁻¹⁵ and the relation between CRP and coronary artery disease (CAD) has been significant in some studies,¹⁶⁻¹⁸ but in others it has not been significant^{17,19-27} and has even been significantly negative in others.^{28,29}

The extent to which CRP levels predict clinical events depends on the relation of CRP to the burden of underlying atherosclerosis or the milieu leading to plaque rupture and thrombosis, and is unknown. Given that CRP levels predict clinical events, it is of substantial interest to dissect the pathophysiology of this relation. In contrast to clinical events, an independent association between CRP levels and coronary¹⁹⁻²⁹ or carotid^{27,30-36} atherosclerosis has not been established clearly. Coronary artery calcification (CAC), measured by electron beam tomography (EBT) or spiral computed tomography, might be useful in identifying novel risk factors for coronary atherosclerosis in asymptomatic subjects.

The amount of CAC at EBT is correlated with the burden of atherosclerosis at both autopsy and coronary angiography,^{37,38} and studies suggest that CAC is a predictor of clinical CAD events in both symptomatic³⁹ and asymptomatic^{40,41} subjects. Studies of CAC might permit differentiation of factors associated with coronary atherosclerosis from those related to plaque rupture or thrombosis. Studies of CRP and CAC in healthy subjects have produced conflicting results. While some studies have found no association between CRP and CAC,¹⁷⁻²⁹ others have reported a weak relation.¹⁶⁻¹⁸ It is unclear whether these conflicting reports reflect the limitations of study design and analysis, or real differences in the pathophysiology of CAC, a measure of coronary atherosclerotic burden, and elevated CRP, a marker of inflammation.

Some support the concept that CAC scores and plasma CRP levels might provide independent and complementary information regarding the risk of cardiovascular events.^{22,42}

Methods

The study population comprised 143 patients with coronary artery disease admitted to our center, an academic tertiary referral center, from December 2006 to March 2007 for coronary artery bypass graft (CABG) surgery. When patients were admitted to our center for CABG, medical history and physical examination were completed and patients were excluded from study if they had a history of the following conditions:

- 1-*myocardial infarction or unstable angina during the previous month,*
- 2-*aortic valve replacement or mitral valve replacement surgery,*
- 3- *CABG surgery or coronary stenting.*

All study participants gave written informed consent. The protocol was approved by the Research Committee of the Iran University of Medical Sciences, Tehran. Age, cardiac risk factors including hypertension, dyslipidemia,

diabetes mellitus, family history of coronary disease, smoking status, and drug history were determined by interview (self-reported), and body mass index (BMI) by examination. Blood sampling was done for lipid profile, creatinine⁴⁴⁻⁴⁶ and hs-CRP and frozen at -70° C for four months. Hs-CRP measurement was done by commercial kits (Pars Azmun Co.), by latex immunoturbid assay and by a single laboratory technician blinded to all clinical and radiologic data. Routine lab data included lipid profile and creatinine, and coronary calcium scoring was done by 10-slice spiral CT scan (Siemens Somatom Sensation 10). Calcium score of the coronary arteries was expressed according to Agston et al.,⁴³ as previously explained. A total CAC score was determined from the sum of individual scores of the 4 major epicardial coronary arteries. All scans were interpreted by a single radiologist blinded to all clinical and serologic data.

Data were analyzed by SPSS 15 software and reported as mean \pm SD if they were continuous and as proportions if they were categorical.

Because some variables did not have normal distribution, we transformed them to logarithmic for normalization of data and because some patients had CCS=0, log (CCS+1) was substituted.

Firstly, we assessed the association between coronary calcium score [log CCS+1] and log (hs-CRP) overall by Pearson correlation coefficient, and then in the presence of any risk factors and any drug use in both sexes by this method.

Because almost all patients used aspirin and beta-blockers, and a negligible percent of patients used calcium channel blockers or gemfibrozil, we did not include them in our analysis. Secondly, we assessed this correlation by multivariable linear regression (enter mode) overall and then according to statins use.

We entered age, BMI, drug history, all risk factors and lipid profile and creatinine in the multivariate analysis.

Results

Table I shows demographic characteristics, CRP levels, and CCS scores in the sample (n=143). Bivariant analysis of CRP and CCS in all patients and subgroups is presented in Table II.

Table I. Characteristics of the study sample.

Age, years	57.7± 9.4
<50	18.2
50-59	39.2
60-69	30.8
>70	11.9
BMI, kg/m²	27.2± 3.5
<24.99	29.4
25-29.99	49
>30	21.6
Tg, mg/dl	153.6± 78.2
Cholesterol, mg/dl	171.4± 48.8
LDL, mg/dl	94.0 ±31.4
HDL, mg/dl	41.0± 37.9
CR, mg/dl	1.37± 0.95
hs-CRP, mg/dl	2.89± 3.43
CCS	366.4± 586.7
Male	74.1
HTN	32.2
DLP	45.5
DM	32.9
C/S	35
FH	14
ACEI/ARB	51.7
Statins	62.2

Values are mean±SD, or percent. BMI=body mass index, Tg=triglyceride, LDL=low density lipoprotein, HDL= high density lipoprotein, CR=creatinine, hs-CRP=high sensitivity CRP, CCS=coronary calcium score, HTN=hypertension, DLP=dyslipidemia, DM=diabetes mellitus, C/S=cigarette smoking, FH=family history of coronary artery disease, ACEI/ARB=angiotensin converting enzyme inhibitor/ angiotensin receptor blocker

This correlation was not significant overall ($r=-0.118$, $P=0.162$), and was significant in 60-69 year-old patients ($r =0.327$, $P=0.031$) and in patients who did not use statins ($r=0.442$, $P=0.001$), this correlation was moderate and significant. In other subgroups this correlation was not significant. Table III shows factors which were associated with CCS, when C - reactive protein is not included in a fully adjusted multivariable linear regression. Age, male sex and family history of coronary artery disease were positive predictors of CCS.

Table II. Correlation of log (hs-CRP) and log (CCS+1) in all cases and subgroups.

GROUP	R	P
MALE	0.122	0.213
FEMALE	0.037	0.828
HTN (+)	0.144	0.339
HTN (-)	0.118	0.248
DLP (+)	0.091	0.469
DLP (-)	0.136	0.236
DM (+)	0.176	0.236
DM (-)	0.096	0.353
FH (+)	0.101	0.673
FH (-)	0.101	0.267
C/S (+)	0.144	0.318
C/S (-)	0.110	0.296
ACEI/ARB (+)	0.091	0.442
ACEI/ARB (-)	0.132	0.281
STATIN (+)	0.006	0.958
STATIN (-)	0.442	0.001
Age <50	0.140	0.944
50-59	0.110	0.420
60-69	0.327	0.031
>70	0.333	0.192
BMI <24.99	0.100	0.528
25-29.99	0.080	0.632
>30	0.323	0.081
ALL CASES	-0.118	0.162

* (+) is presence of the condition and (-) is absence of the condition.

Table III. Multivariate analysis of factors associated with coronary calcium score when C-reactive protein is not included in the analysis.

	B	SD	P
(Constant)	1.173	1.323	0.377
AGE	0.034	0.008	0.000
SEX	-0.409	0.191	0.035
HTN	0.304	0.177	0.089
DLP	0.019	0.163	0.909
DM	0.121	0.165	0.464
FH	0.470	0.212	0.028
C/S	0.058	0.172	0.735
ACEI/ARB	-0.069	0.153	0.651
STATIN	-0.146	0.157	0.355
LDL	0.000	0.003	0.859
LogHDL	0.138	0.184	0.455
LogTG	-0.182	0.159	0.257
LogCR	-0.134	0.252	0.598
BMI	-0.014	0.021	0.514

*Results of linear regression (log of (CCS+1) as the dependent variable) are presented when CRP is not included in analysis, as the change log(CCS+1) for a specific change in risk factor. Models were adjusted for the following variables; age, sex, history of hypertension, history of dyslipidemia, diabetes mellitus, family history of coronary artery disease, smoking, use of the following medications: statins, ACEI/ARB ,LDL[log LDL] ,HDL[logHDL], TG[logTG], CR[logCR], body mass index.

Factors which were associated with CCS, when C - reactive protein is included in the fully adjusted multivariate linear regression are shown in Table IV. Age was the only predictor of CCS in the presence of CRP, and sex and family history of coronary artery disease were not predictors of CCS after adjustment for CRP level.

Table IV. Multivariable analysis of factors associated with coronary calcium score when C- reactive protein is included in the analysis.

	B	SD	P
(Constant)	1.046	1.312	0.427
AGE	0.037	0.008	0.000
SEX	-0.343	0.193	0.078
HTN	0.293	0.176	0.099
DLP	-0.005	0.161	0.977
DM	0.141	0.164	0.392
FH	0.395	0.213	0.067
C/S	0.068	0.170	0.688
ACEI/ARB	-0.032	0.153	0.834
STATIN	-0.204	0.158	0.200
LDL	0.001	0.003	0.657
LogHDL	0.089	0.184	0.630
LogTG	-0.169	0.158	0.288
LogCR	-0.063	0.253	0.802
BMI	-0.013	0.021	0.542
LogCRP	-0.115	0.061	0.062

*Results of linear regression (log of (CCS+1) as the dependent variable) are presented when CRP is included in analysis as the change log(CCS+1) for a specific change in risk factor. Models were adjusted for the following variables; age, sex, history of hypertension, history of dyslipidemia, diabetes mellitus, family history of coronary artery disease, smoking, use of the following medications: statins, ACEI/ARB ,LDL[log LDL] ,HDL[logHDL] TG[logTG] ,CR[logCR], body mass index and CRP [logCRP].

Because in bivariate analysis the association of log (CRP) and log (CCS+1) was significant in patients who did not use statins, we analyzed this association in patients in fully adjusted, multivariate linear regression. Table V shows this analysis. Male sex and family history of coronary artery disease are positive predictors of CCS, and CRP was negative predictor of CCS (P=0.008) in patients who did not use statins.

Table V. Multivariable analysis of factors associated with coronary calcium score and C - reactive protein in patients not using statins.

	B	SD	P
(Constant)	3.774	1.682	0.031
AGE	0.021	0.012	0.088
SEX	-0.653	0.262	0.017
HTN	0.318	0.259	0.227
DLP	0.086	0.243	0.724
DM	0.250	0.226	0.276
FH	0.682	0.318	0.038
C/S	-0.346	0.275	0.215
ACEI/ARB	0.191	0.231	0.414
LDL	0.004	0.004	0.294
LogHDL	0.188	0.219	0.396
LogTG	-0.261	0.241	0.285
LogCR	-0.531	0.292	0.077
BMI	-0.068	0.037	0.077
LogCRP	-0.278	0.100	0.008

*Results of linear regression (log of (CCS+1) as the dependent variable) are presented in patients that not use statin, as the change log (CCS+1) for a specific change in risk factor. Models were adjusted for the following variables; age, sex, history of hypertension, history of dyslipidemia, diabetes mellitus, family history of coronary artery disease, smoking, use of the following medications: statins, ACEI/ARB ,LDL[log LDL] ,HDL[logHDL] ,TG[logTG] ,CR[logCR], body mass index and CRP [logCRP]

Discussion

CCS measured at spiral CT might be useful for identifying novel risk factors and exploring the relation of risk factors with coronary atherosclerosis. We have examined the association between plasma CRP and CCS in patients who were candidates for CABG. In previous studies, subjects of the study were suspected to have coronary artery disease without any documentation as proof, but in our study we selected patients who had coronary artery disease documented and confirmed by selective coronary artery angiography. We found no evidence of a positive association between hs-CRP and calcium scores. Indeed, if anything, these data suggest an inverse relationship between hs-CRP levels and coronary calcium in patients who did not use statins.

Nonetheless, we believe the lack of a positive association between hs-CRP and coronary calcium score deserves careful consideration. The lack of correlation in the current data between spiral CT score and hs-CRP suggests that calcification may be less likely to reflect inflammation per se; spiral CT-detected calcification may predominantly be a marker for mature and hence stable atherosclerotic plaque, and thus only be an indirect marker for the presence of uncalcified rupture-prone lesions, which may be more likely markers for future cardiac events, but a correlation between soft, noncalcified plaque was not confirmed.²⁴ Deposition of calcium in atherosclerotic lesions has been shown to be an active process analogous to the formation of bone spicules.⁴⁷ Furthermore, it appears to involve cells of special embryonic lineage. Thus, coronary calcification may not merely be a direct consequence of atherogenesis but rather may depend upon the presence of specific determinants independent of the central processes involved in plaque formation. The reasons for the lack of association between CRP and CCS, in contrast to a more consistent association between CRP and clinical events, are unclear. However, this finding supports the concept that CRP levels might not be related to atherosclerosis per se, distinct from being a marker of plaque rupture and thrombosis. Therefore, CRP might not be useful in identifying the underlying mechanisms of atherosclerosis initiation or progression. The present findings suggest that the relationship between higher CRP levels and incident cardiovascular events may reflect the composition, morphology, and stability of plaque rather than overall atherosclerotic burden.⁴⁸ Because CCS are associated with risk for subsequent cardiovascular events and provide a measure of disease processes distinct from CRP, these two measures may be complementary rather than competitive for risk prediction.⁴² This study, demonstrating that hs-CRP is unrelated to the presence and severity of

clinical calcified atherosclerosis, suggests that serologic inflammatory markers are principally a measure of the athero-inflammatory disease process and are not an index of the extent of coronary atherosclerotic plaque. The independent prognostic utility of quantifying calcified atherosclerosis and systemic inflammation suggests that disease and process markers of atherosclerosis may be complementary tools in coronary heart disease prediction.

We used a validated commercial assay for the measurement of hs-CRP, but variability in commercial assays may limit the validity of these data. We used CCS as a surrogate for coronary atherosclerotic plaque burden on the basis of the well-established relationship between CCS and the extent of histologic plaque.³⁷ However, atherosclerosis in vascular beds other than the coronary arteries could also contribute to the level of hs-CRP.⁴⁹

Funding Sources

This research was done with financial support from Iran University of Medical Sciences.

Conflict of Interest

No conflicts of interest have been claimed by the authors.

References

1. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. *Stroke* 2006; 37: 1923-32.
2. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. *J Atheroscler Thromb* 2003; 10: 63-71.
3. Niccoli G, Biasucci LM, Biscione C, Fusco B, Porto I, Leone AM, Bona RD, Dato I, Liuzzo G, Crea F. Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. *Atherosclerosis* 2008; 196: 779-85.
4. Zhang SZ, Jin YP, Qin GM, Wang JH. Association of platelet-monocyte aggregates with platelet activation, systemic inflammation,

- and myocardial injury in patients with non-ST elevation acute coronary syndromes. *Clin Cardiol* 2007; 30: 26-31.
5. Correia LC, Lima JC, Rocha MS, D'Oliveira Junior A, Péricles Esteves J. Does high-sensitivity C-reactive protein add prognostic value to the TIMI-risk score in individuals with non-ST elevation acute coronary syndromes? *Clin Chim Acta* 2007; 375: 124-8.
 6. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. *Int J Cardiol* 2006; 109: 248-56.
 7. Sanchez PL, Morinigo JL, Pabon P, Martin F, Piedra I, Palacios IF, Martin-Luengo C. Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome. *Heart* 2004; 90: 264-9.
 8. Zairis MN, Adamopoulou EN, Manousakis SJ, Lyras AG, Bibis GP, Ampartzidou OS, et al. Biomarkers of Inflammation and Outcome in Acute Coronary Syndromes (BIAS) Investigators. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. *Atherosclerosis* 2007; 194: 397-402.
 9. Onat A, Can G, Hergenç G. Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. *Metabolism* 2008; 57: 207-14.
 10. Hung J, Knuiman MW, Divitini ML, Davis T, Beilby JP. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. *Am J Cardiol* 2008; 101: 193-8.
 11. Tohidi M, Hadaegh F, Harati H, Azizi F. C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. *Int J Cardiol Epub* 2008.
 12. Arena R, Arrowood JA, Fei DY, Helm S, Kraft KA. The relationship between C-reactive protein and other cardiovascular risk factors in men and women. *J Cardiopulm Rehab* 2006; 26: 323-7.
 13. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JS, Raitakari OT. Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: The Cardiovascular Risk in Young Finns Study. *J Intern Med* 2005; 258: 428-34.
 14. Williams MJ, Williams SM, Milne BJ, Hancox RJ, Poulton R. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. *Int J Obes Relat Metab Disord* 2004; 28: 998-1003.
 15. Saito I, Sato S, Nakamura M, Kokubo Y, Mannami T, Adachi H, Konishi M, et al. A low level of C-reactive protein in Japanese adults and its association with cardiovascular risk factors: the Japan NCV-Collaborative Inflammation Cohort (JNIC) study. *Atherosclerosis* 2007; 194: 238-44.
 16. Wang TJ, Martin G, Larson GM, Levy D, Benjamin EJ, Kupka MJ, et al. C-reactive protein is associated with subclinical epicardial coronary calcification in men and women. The Framingham Heart Study. *Circulation* 2002; 106: 1189-1191.
 17. Colhoun HM, Schalkwijk C, Rubens MB, Stehouwer CDA. C-reactive protein in type 1 diabetes and its relationship to coronary artery calcification. *Diabetes Care* 2002; 25: 1813-1817.
 18. Erbel R, Möhlenkamp S, Lehmann N, Schermund A, Moebus S, Stang A, et al. On behalf of the Heinz Nixdorf Recall Study Investigative Group. Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. *Atherosclerosis* 2008; 197: 662-72.
 19. Hunt ME, O'Malley PG, Vernalis MN, Feuerstein IM, Taylor AJ. C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. *Am Heart J* 2001; 141: 206-10.
 20. Newman AB, Barbara L, Naydeck BL, Sutton-Tyrrell K, Feldman A, Edmundowicz D, Kuller, LH. Coronary artery calcification in older adults to age 99; prevalence and risk factors. *Circulation* 2001; 104: 2679-2684.
 21. Reilly, MP, Wolfe, ML, Russell Localio A, Rader, DJ. C-reactive protein and coronary

- artery calcification. The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA). *Arterioscler Thromb Vasc Biol* 2003; 23: 1851-1856.
22. Arad Y, Goodman JK, Roth M, Newstein D, Guerci AD. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events. The St. Francis Heart Study. *J Am Coll Cardiol* 2005; 46: 158-65.
 23. Huang HP, Chen LC, Leu HB, Ding PY, Jaw-Wen Chen JW, Wu TC, Lin SJ. Enhanced coronary calcification determined by electron beam CT is strongly related to endothelial dysfunction in patients with suspected coronary artery disease. *Chest* 2005; 128: 810-815.
 24. Khera A, de Lemos JA, Peshock RM, Lo HS, Stanek HG, Murphy SA, Wians FH, Grundy SM, McGuire DK. Relationship between C-reactive protein and subclinical atherosclerosis. The Dallas Heart Study. *Circulation* 2006; 113: 38-43.
 25. Anand DV, Lim E, Darko D, Hopkins PBD, Lipkin D, Corder R, Lahiri A. Determinants of progression of coronary artery calcification in type 2 diabetes: role of glycemic control and inflammatory/vascular calcification markers. *J Am Coll Cardiol* 2007; 50: 2218-25.
 26. Coutinho TA, Turner ST, Peyser PA, Bielak LF, Sheedy PF, Kullo IJ. Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. *AJH* 2007; 20: 83-89.
 27. Elias-Smale SE, Kardys I, Oudkerk M, Hofman A, Witteman JCM. C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study. *Atherosclerosis* 2007; 195: e195-e202.
 28. Redberg RF, Rifai N, Gee L, Ridker PM. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: Implications for coronary artery disease screening. *J Am Coll Cardiol* 2000; 36: 39-43.
 29. Godtsland IF, Elkeles RS, Feher MD, Nugara F, Rubens MB, Richmond W, Khan M, Donovan J, Anyaoku V, Flather MD for the PREDICT Study Group. Coronary calcification, homocysteine, C-reactive protein and the metabolic syndrome in type 2 diabetes: the Prospective Evaluation of Diabetic Ischaemic Heart Disease by Coronary Tomography (PREDICT) Study. *Diabet Med* 2006; 23, 1192-1200.
 30. Mullenix PS, Steele SR, Martin MJ, Starnes BW, Andersen CA. C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis. *Arch Surg* 2007; 142: 1066-71.
 31. Schlager O, Exner M, Mlekusch W, Sabeti S, Amighi J, Dick P, Wagner O, Koppensteiner R, Minar E, Schillinger M. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. *Stroke* 2007; 38: 1263-8.
 32. Sander K, Horn CS, Briesenick C, Sander D; INVADE Study Group. High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE Study. *Stroke* 2007; 38: 2881-6.
 33. Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH, Kuller LH, Cushman M. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. *Circulation* 2007; 116: 32-8.
 34. Thakore AH, Guo CY, Larson MG, Corey D, Wang TJ, Vasani RS, D'Agostino RB Sr, Lipinska I, Keaney JF Jr, Benjamin EJ, O'Donnell CJ. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). *Am J Cardiol* 2007; 99: 1598-602.
 35. Lorenz MW, Karbstein P, Markus HS, Sitzer M. High-sensitivity C-reactive protein is not associated with carotid intima-media progression: the carotid atherosclerosis progression study. *Stroke* 2007; 38: 1774-9.
 36. Arthurs ZM, Andersen C, Starnes BW, Sohn VY, Mullenix PS, Perry JA. Prospective evaluation of C-reactive protein in the progression of carotid artery stenosis. *J Vasc Surg* 2008; 47: 744-50.
 37. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery

- calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. *Circulation* 1995; 92: 2157–2162.
38. Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. *Mayo Clin Proc* 1999; 74: 243–252.
 39. Möhlenkamp S, Lehmann N, Schermund A, Pump H, Moebus S, Baumgart D, Seibel R, Grönemeyer DH, Jöckel KH, Erbel R. Prognostic value of extensive coronary calcium quantities in symptomatic males - a 5-year follow-up study. *Eur Heart J* 2003; 24: 845-54.
 40. Lakoski SG, Greenland P, Wong ND, Schreiner PJ, Herrington DM, Kronmal RA, Liu K, Blumenthal RS. Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). *Arch Intern Med* 2007; 167: 2437-42.
 41. Becker A, Leber A, Becker C, Knez A. Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. *Am Heart J* 2008; 155: 154-60.
 42. Park R, Detrano R, Xiang M, Fu P, Ibrahim Y, LaBree L, Azen S. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in non-diabetic individuals. *Circulation* 2002; 106: 2073-7.
 43. Agatston AS, Janowitz WR, Hildner FJ. Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol* 1990; 15: 827– 832.
 44. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. *Nephrol Dial Transplant* 2001; 16: 1189-97.
 45. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. *Am J Kidney Dis* 2004; 43: 244-53.
 46. Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. *Kidney Int* 2005; 68: 1258-66.
 47. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. *Arterioscler Thromb Vasc Biol* 2004; 24: 1161-70.
 48. Taylor AJ, Burke AP, O'Malley PG, Farb A, Malcom GT, Smialek J, Virmani R. A comparison of the Framingham risk index, coronary artery calcification, and culprit plaque morphology in sudden cardiac death. *Circulation* 2000; 101: 1243–1248.
 49. Shankar A, Li J, Nieto FJ, Klein BE, Klein R. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. *Am Heart J* 2007; 154: 495-501.